Resources Repository
-
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Technology Assessment | Infectious Diseases | Probability/Bayes | Test Performance | Health Systems | Policy/Regulation | Government/Law | Health/Medicine | Global | North America -
ArticlePublication 2020Economic Evaluation of HBV Birth Dose Vaccination
This article, published in Cost Effectiveness and Resource Allocation, examines the cost-effectiveness of a birth …
This article, published in Cost Effectiveness and Resource Allocation, examines the cost-effectiveness of a birth dose of HBV vaccine in a medical setting in Ethiopia. The authors construct a decision analytic model with a Markov process to estimate the costs and effects of a birth dose of HBV vaccine, compared with current practices in Ethiopia. Based on the cost-effectiveness findings, introducing a birth dose of HBV vaccine in Ethiopia would likely be highly cost-effective. Such…
Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2020Financial Burden of HIV and TB
This article, published in BMJ Open, aims to estimate the household economic burden and incidence …
This article, published in BMJ Open, aims to estimate the household economic burden and incidence of catastrophic health expenditures (CHE) incurred as a result of HIV and TB care across income quintiles in Ethiopia. The economic burden of HIV and TB care is estimated looking at direct and indirect costs, whereas the incidence of CHE is determined using direct costs that exceed 10% of the household income threshold. HIV and TB are found to cause…
Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Health/Medicine | Sub-Saharan Africa -
ToolInteractive, Teaching Resource 2020RAND Critical Care Surge Response Tool
This Excel-based model allows decisionmakers at all levels (i.e., hospitals, health care systems, states, regions) …
This Excel-based model allows decisionmakers at all levels (i.e., hospitals, health care systems, states, regions) to examine the current critical care capacity in the nation’s hospitals and rapidly explore strategies for increasing capacity to provide care for the sickest COVID-19 patients. The tool was developed by the RAND Corporation in response to the 2020 COVID-19 pandemic. Model input parameters to the Excel spreadsheet include baseline number of beds, critical care doctors and nurses, respiratory therapists,…
Operations Research | Infectious Diseases | Priority Setting/Ethics | Mathematical Models | Health/Medicine | North America | Professional | Policy Translation -
ArticlePublication 2020Health Gains & Financial Risk Protection Afforded by Public Financing of Selected Malaria Interventions in Ethiopia: An ECEA
This article, published in the Malaria Journal, aims to estimate the expected health and financial …
This article, published in the Malaria Journal, aims to estimate the expected health and financial risk protection (FRP) benefits of universal public financing of key malaria interventions in Ethiopia. An extended cost-effectiveness analysis (ECEA) is used to estimate the potential health and FRP benefits of publicly financing a 10% increase in artemisinin-based combination therapy (ACT), long-lasting insecticide-treated bed nets (LLIN), indoor residual spraying (IRS), and a hypothetical malaria vaccine. The results indicate that ACT, LLIN,…
Cost-Effectiveness Analysis | Infectious Diseases | Priority Setting/Ethics | Social Determinants | Health Systems | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2019Health and Financial Benefits of Averting Malaria in Zambia: An ECEA
This study used the extended cost-effectiveness analysis (ECEA) to examine impact of the hypothetical rollout …
This study used the extended cost-effectiveness analysis (ECEA) to examine impact of the hypothetical rollout of the malaria vaccine RTS,S/AS01 in Zambia on the health benefits of children under five, and financial benefits on their households. The authors assumed a three-dose vaccination schedule (over 6-9 months), and vaccine cost of US$5 per dose. To assess vaccine impact, for each income quintile, they computed the number of under-five malaria deaths prevented, the household out-of-pocket (OOP) malaria-related…
Cost-Effectiveness Analysis | Infectious Diseases | Priority Setting/Ethics | Mathematical Models | Health Systems | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2018Poverty Reduction & Equity Benefits of Measles, Rotavirus and Pneumococcal Vaccines in LMICs
This study uses the extended cost effectiveness analysis (ECEA) to evaluate the impact of immunization …
This study uses the extended cost effectiveness analysis (ECEA) to evaluate the impact of immunization against measles, severe pneumococcal disease and severe rotavirus for birth cohorts vaccinated over 2016–2030 for three scenarios in 41 Gavi-eligible countries: no immunization, current immunization coverage forecasts and the current immunization coverage enhanced with funding support. Following the distribution of the cases by socioeconomic group, the study found that the number of catastrophic health costs (CHC) cases attributable to measles,…
Cost-Effectiveness Analysis | Infectious Diseases | Priority Setting/Ethics | Mathematical Models | Child/Nutrition | Health/Medicine | Global -
ArticlePublication 2019Systematic Review of Economic Evaluations of Vaccination Strategies Against Tuberculosis
Bacillus Calmette-Guérin (BCG) is the only licensed vaccine for tuberculosis, but its effectiveness is limited …
Bacillus Calmette-Guérin (BCG) is the only licensed vaccine for tuberculosis, but its effectiveness is limited and varies by age, so a valid cost-effectiveness study is needed to assist decision-makers in the implementation of cost-effective strategies for BCG vaccination. Using the Quality of Health Economic Studies (QHES) instrument, the authors assessed the quality of published studies involving economic evaluations of BCG vaccination strategies in a variety of regions, target populations, and vaccine types. Most of the…
Cost-Effectiveness Analysis | Infectious Diseases | Evidence Synthesis | Mathematical Models | Health/Medicine | Global -
ArticlePublication 2019Decision-Making for Universal Access to Tuberculosis Diagnosis In India
The authors evaluated the costs of centralized and decentralized testing for tuberculosis with Xpert MTB/RIF …
The authors evaluated the costs of centralized and decentralized testing for tuberculosis with Xpert MTB/RIF (Xpert), a WHO-endorsed test. They used an agent-based simulation of TB transmission in a hypothetical representative region in India to assess the impact and cost-effectiveness of various strategies to provide universal access to diagnosis and drug susceptibility testing (DST) for tuberculosis. The authors found that decentralization was most favorable compared to centralized testing when volume at decentralized facilities was high,…
Cost-Effectiveness Analysis | Infectious Diseases | Microsimulation | Health/Medicine | Asia & Pacific